People taking the drugs had a lower risk of organ failure and death However, the drugs were associated with an increased risk ...

It was the first in a series of drugs that are, for the first time, effective against obesity and can help lessen the moral ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

What about the side-effects? Will I regain all my weight? Dr Sarah Jarvis has the answers to your burning questions.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Consumers taking GLP-1 drugs like Ozempic will need to adapt their shopping habits and diets, opening opportunities for food ...

Food companies may be able to satisfy the needs of the growing cohort of GLP-1 medication users while also targeting a ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...